Skip to main content

Table 2 Respondents preferences for colorectal cancer screening

From: Public stated preferences and predicted uptake for genome-based colorectal cancer screening

Attribute level β − coefficient 95% CI
Preparation   
  No preparation 0.38 (0.02)a 0.34 to 0.42
  Laxatives −0.03 (0.01)b −0.06 to -0.01
  Enemas −0.16 (0.01)a −0.19 to -0.13
  Diet plus laxatives# −0.19 (0.02)a −0.22 to -0.16
Technique   
  Pill 0.48 (0.02)a 0.44 to 0.52
  Stool 0.24 (0.02)a 0.20 to 0.28
  Long tube with sedation# −0.34 (0.02)a −0.39 to -0.30
  Short tube −0.37 (0.02)a −0.41 to -0.33
Sensitivity   
  100% 0.36 (0.02)a 0.32 to 0.39
  90% 0.08 (0.01)a 0.05 to 0.10
  80% −0.14 (0.01)a −0.17 to -0.11
  70%# −0.30 (0.02)a −0.33 to -0.26
Specificity   
  100% 0.15 (0.01)a 0.12 to 0.17
  90% 0.06 (0.01)a 0.03 to 0.09
  80% −0.04 (0.01)a −0.07 to -0.02
  70%# −0.16 (0.02)a −0.19 to -0.13
Complications   
  None 0.14 (0.02)a 0.11 to 0.17
  1/10.000 0.04 (0.01)a 0.01 to 0.06
  10/10.000 −0.04 (0.01)a −0.07 to 0.02
  100/10.000# −0.13 (0.02)a −0.16 to -0.10
Frequency   
  Biennial 0.17 (0.02)a 0.14 to 0.21
  Annual# 0.03 (0.02) −0.01 to 0.07
  Every 5 years 0.01 (0.02) −0.03 to 0.04
  Every 10 years −0.21 (0.02)a −0.26 to -0.17
No screening −0.29 (0.03)a −0.36 to -0.23
  1. #: reference level in effects coding; ap-value < 0.005; bp-value < 0.05; 65079 Observations, 1356 respondents. McFadden R2 = 11.0%.